Picture of 2Seventy Bio logo

TSVT 2Seventy Bio Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-31.11%
3m-1.91%
6m-14.9%
1yr-70.2%
Volume Change (%)
10d/3m-27.73%
Price vs... (%)
52w High-68.4%
50d MA-14.63%
200d MA-27.13%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-46.99%
Return on Equity-76.91%
Operating Margin-236.69%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of 2Seventy Bio EPS forecast chart

Profile Summary

2seventy bio, Inc. is a cell and gene therapy company, which is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The Company’s advancing multiple clinical programs, including SC-DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia (AML), and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma, or B-NHL, as well as multiple preclinical programs, including bbT4015, an engineered CAR T cell therapy targeting MUC16. Additionally, together with its partner Bristol Myers Squibb, the Company is delivering Abecma to multiple myeloma patients in the United States.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    April 26th, 2021
    Public Since
    October 18th, 2021
    No. of Shareholders
    13
    No. of Employees
    274
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Select Market
    Shares in Issue
    51,311,132

    TSVT Share Price Performance

    Upcoming Events for TSVT

    Q1 2024 2Seventy Bio Inc Earnings Release

    2Seventy Bio Inc Annual Shareholders Meeting

    Q2 2024 2Seventy Bio Inc Earnings Release

    Similar to TSVT

    Picture of 4D Molecular Therapeutics logo

    4D Molecular Therapeutics

    us flag iconNASDAQ Global Select Market

    Picture of AbCellera Biologics logo

    AbCellera Biologics

    us flag iconNASDAQ Global Select Market

    Picture of AbSci logo

    AbSci

    us flag iconNASDAQ Global Select Market

    Picture of Acadia Pharmaceuticals logo

    Acadia Pharmaceuticals

    us flag iconNASDAQ Global Select Market

    Picture of Acelyrin logo

    Acelyrin

    us flag iconNASDAQ Global Select Market

    FAQ